| 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||
| <<APR | MAY | JUN>> | |||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||
Lifesciences, Outsourcing, and Growth Opportunities in India
The U.S. biopharma industry is facing several emerging challenges, triggering the need for a new business model for the industry. As R&D costs escalate and R&D productivity stagnates, pharma companies face increasing pressures to outsource several tasks and R&D processes. At the same time, India’s emerging lifesciences industry has demonstrated nascent capabilities in both discovery and clinical development, and promises to provide a complementary set of capabilities to U.S. and European biopharma companies. With the enforcement of the WTO TRIPS agreement in January 2005, intellectual property (IP) issues are expected to become less of a hurdle, potentially triggering a dramatic shift in the global biopharma industry. The keynote speaker and panelists will discuss these issues and present their opinions.
Panelists:
Kelly Blackburn, Millennium Pharmaceuticals
Dr. Nick Terrett, Pfizer Inc.
Dr. Govinda Rao, Vertex Pharmaceuticals
John Serio, Attorney, Brown Rudnick Berlack Israels
Dr. Anil Khurana, Access International Partners, LLC
Dr. Jugnu Jain, Vertex Pharmaceuticals
Date: 02/17/2005
Location: Millennium Pharmaceuticals Main Lobby, 35 Landsdowne Street, Cambridge, MA 02139
Time: 6:30 pm – 9:30 pm
Contact: Dr. Jugnu Jain 617 444 6132
Web: http://www.tie-boston.org
Directions: http://www.mlnm.com/contactus.asp